1-5 of 5
Authors: Masahiro Yao
Journal Article
Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up Open Access
Japanese Journal of Clinical Oncology, Volume 50, Issue 1, January 2020, Pages 12–19, https://doi.org/10.1093/jjco/hyz132
Published: 21 October 2019
Journal Article
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study Get access
Japanese Journal of Clinical Oncology, Volume 49, Issue 6, June 2019, Pages 506–514, https://doi.org/10.1093/jjco/hyz026
Published: 22 February 2019
Journal Article
Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study Open Access
Japanese Journal of Clinical Oncology, Volume 47, Issue 7, July 2017, Pages 639–646, https://doi.org/10.1093/jjco/hyx049
Published: 13 April 2017
Journal Article
Predictors of poor response to secondary alternative antiandrogen therapy with flutamide in metastatic castration-resistant prostate cancer Get access
Japanese Journal of Clinical Oncology, Volume 46, Issue 11, November 2016, Pages 1042–1046, https://doi.org/10.1093/jjco/hyw110
Published: 24 October 2016
Journal Article
Transition of Organizational Category on Renal Cancer Get access
Japanese Journal of Clinical Oncology, Volume 43, Issue 3, March 2013, Pages 233–242, https://doi.org/10.1093/jjco/hyt006
Published: 06 February 2013
